Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma
Conditions
Brief summary
A study of CTA30X cell injection in the treatment of relapsed or refractory CD19-positive B-line hematological malignancies
Detailed description
This is a single arm, open-label, single-center study. This study is indicated for relapsed or refractory CD19+ B-line hematological malignancy: B-ALL and B-NHL. the selection of dose levels and the number of subjects are based on clinical tiral of similar foreign products. 3 groups of patients will be enrolled, 36 in each group. Primary objective is to explore the safety, main consideration is dose-related safety.
Interventions
DRUGCTA30X
CTA30X cell injection by intravenous infusion
Sponsors
Nanjing Bioheng Biotech Co., Ltd.
He Huang
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
3 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
Inclusion criteria applicable to ALL only: 1. Male or female aged ≥ 3 and \<70 years old; 2. Histologically confirmed diagnosis of CD19+ B-ALL per the US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Acute Lymphoblastic Leukemia (2016.v1); 3. Relapsed or refractory CD19+ B-ALL (meeting one of the following conditions): 1. CR not achieved after standardized chemotherapy; 2. CR achieved following the first induction, but CR duration is ≤ 12 months; 3. Ineffective after first or multiple remedial treatments; 4. 2 or more recurrences; 4. The number of primordial cells (lymphoblast and prolymphocyte) in bone marrow is \>5% (morphology) and/or \>1% (Flow cytometry); 5. Philadelphia-chromosome-negative (Ph-) patients; or Philadelphiachromosome-positive (Ph+) patients who cannot tolerate TKI treatments or do not respond to 2 TKI treatments; Inclusion criteria applicable to NHL only: 1. Male or female aged ≥ 18 and \<70 years old; 2. Histologically confirmed diagnosis per WHO Classification Criteria for Lymphocytic Tumors 2016, including DLBCL(NOS), follicular lymphoma, Chronic lymphoblastic leukemia/small lymphoblastic lymphoma transforms DLBCL, PMBCL and high grade B cell lymphoma; 3. Relapsed or refractory DLBCL (meeting one of the following conditions): 1. No remission or recurrence after receiving second-line or above chemotherapy; 2. Primary drug resistance; 3. Recurrence after autologous hematopoietic stem cell transplantation Applicable standards for ALL and NHL: 1. Total bilirubin ≤ 51umol/L, ALT and AST ≤ 3 times of upper limit of normal, creatinine ≤ 176.8umol/L; 2. Echocardiogram shows left ventricular ejection fraction (LVEF) ≥ 50%; 3. No active infection in the lungs, blood oxygen saturation by sucking air is ≥92%; 4. Estimated survival time ≥ 3 months; 5. ECOG performance status 0 to 2;
Exclusion criteria
1. Patients with extramedullary lesions, except those with CNSL (CNS-1) under effective control (for ALL patients only); 2. Confirmed diagnosis of lymphoblastic crisis of chronic myeloid leukemia, Burkitt's leukemia/lymphoma per WHO Classification Criteria (for ALL patients only); 3. Patients with hereditary syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome (for ALL patients only); 4. Patients with intracranial extralateral lesions (cerebrospinal fluid tumor cells and/or intracranial lymphoma invasion shown by MRI) (for NHL patients only); 5. Extensive involvement of gastrointestinal lymphoma (for NHL patients only); 6. Radiotherapy, chemotherapy and monoclonal antibody within 1 week before screening; 7. Have a history of allergy to any of the components in the cell products; 8. Prior treatment with any CAR T cell product or other genetically-modified T cell therapies; 9. According to the New York heart association (NYHA) cardiac function classification criteria, Subjects with grade III or IV cardiac insufficiency; 10. Myocardial infarction, cardioangioplasty or stenting, unstable angina pectoris, or other severe cardiac diseases within 12 months of enrollment; 11. Severe primary or secondary hypertension of grade 3 or above (WHO Hypertension Guidelines, 1999); 12. Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past; 13. History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular hemorrhagic diseases; 14. Patients with severe active infections (excluding simple urinary tract infection and bacterial pharyngitis). 15. History of other primary cancer, except for the following conditions: 1. Cured non-melanoma after resection, such as basal cell carcinoma of the skin; 2. Cervical cancer in situ, localized prostate cancer, ductal cancer in situ with disease-free survival ≥ 2 years after adequate treatment; 16. Patients with autoimmune diseases requiring treatment, patients with immunodeficiency or requiring immunosuppressive therapy; 17. Patients with graft-versus-host disease (GVHD); 18. If HBsAg positive at screening, HBV DNA copy number detected by PCR in patients with active hepatitis B \> 1000 (if HBV DNA copy number≤1000, routine antiviral therapy is required after enrollment), as well as CMV, hepatitis C, syphilis infection; 19. Patients who have participated in any other clinical studies within 2 weeks prior to screening; 20. Pregnant and breast-feeding women and the subjects who are fertile and unable to take effective contraceptive measures (regardless of the gender); 21. Any situations that the investigator believes may increase the risk of patients or interfere with the results of study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose-limiting toxicity (DLT) | Baseline up to 28 days after CTA30X infusion | Adverse events assessed according to NCI-CTCAE v5.0 criteria |
| Incidence of treatment-emergent adverse events (TEAEs) | Up to 2 years after CTA30X infusion | Incidence of treatment-emergent adverse events \[Safety and Tolerability\] |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| B-ALL, ORR | Month 6, 12, 18 and 24 | Assessment of ORR at Month 6, 12, 18 and 24 |
| B-cell acute lymphocytic leukemia (B-ALL), Overall response rate (ORR) | Month 1 and 3 | Assessment of ORR (ORR = CR + CRi ) at Month 1 and 3 |
| B cell non-hodgkin's lymphoma (B-NHL), Overall response rate (ORR) | weeks 4, 12, months 6, 12, 18 and 24 | Assessment of ORR (ORR = CR + PR ) per Lugano 2014 criteria |
| B-ALL, Event-free survival (EFS) | Month 6, 12, 18 and 24 | From the first infusion of CTA30X to the occurrence of any event, including death, relapse or gene relapse, disease progression (any one occurs first), and the last visit |
| B-ALL, MRD negative overall response rate (MRD- ORR) | 3 months | Assessment of MRD negative overall response rate (MRD- ORR) at 3 months after CTA30X infusion |
Countries
China
Outcome results
None listed